Terlipressin

Terlipressin, sold under the brand name Terlivaz among others, is an analogue of vasopressin used as a vasoactive drug in the management of low blood pressure. It has been found to be effective when norepinephrine does not help. Terlipressin is a vasopressin receptor agonist.

Terlipressin was approved for medical use in the United States in 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Terlipressin is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.

Indications for use include norepinephrine-resistant septic shock although, 2021 Surviving Sepsis Guidelines recommend against its use for adults with septic shock and hepatorenal syndrome. In addition, it is used to treat bleeding esophageal varices.

Terlipressin is contraindicated in people experiencing hypoxia or worsening respiratory symptoms and in people with ongoing coronary, peripheral or mesenteric ischemia. Terlipressin may cause fetal harm when used during pregnancy.

Terlipressin is available in United States, New Zealand, Australia, the European Union, India, Indonesia, Pakistan, UAE. It is sold under various brand names including Glypressin and Terlivaz.